Claims
- 1-28. (Canceled)
- 29. A polynucleotide comprising a coding sequence for a multiple epitope fusion antigen, wherein said multiple epitope fusion antigen comprises the amino acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:4), or an amino acid sequence with at least 80% sequence identity thereto which reacts specifically with anti-HCV antibodies that specifically react with SEQ ID NO:4 present in a biological sample from an HCV-infected individual.
- 30. The polynucleotide of claim 29, wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:4) which reacts specifically with anti-HCV antibodies that specifically react with SEQ ID NO:4 present in a biological sample from an HCV infected individual.
- 31. The polynucleotide of claim 29, wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that comprises an amino acid sequence with at least 98% sequence identity to the amino acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:4) which reacts specifically with anti-HCV antibodies that specifically react with SEQ ID NO:4 present in a biological sample from an HCV infected individual.
- 32. The polynucleotide of claim 29, wherein said polynucleotide comprises a coding sequence for a multiple epitope fusion antigen that consists of the amino acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:4).
- 33. The polynucleotide of claim 29, wherein said polynucleotide comprises the nucleic acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:3), or a nucleic acid sequence with at least 80% sequence identity thereto which encodes a polypeptide that reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.
- 34. The polynucleotide of claim 29, wherein said polynucleotide comprises the nucleic acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:3), or a nucleic acid sequence with at least 90% sequence identity thereto which encodes a polypeptide that reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.
- 35. The polynucleotide of claim 29, wherein said polynucleotide comprises the nucleic acid sequence depicted in FIGS. 5A-5F (SEQ ID NO:3), or a nucleic acid sequence with at least 98% sequence identity thereto which encodes a polypeptide that reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.
- 36. A recombinant vector comprising:
(a) a polynucleotide according to claim 29;(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
- 37. A recombinant vector comprising:
(a) a polynucleotide according to claim 32;(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
- 38. A recombinant vector comprising:
(a) a polynucleotide according to claim 33;(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
- 39. A recombinant vector comprising:
(a) a polynucleotide according to claim 35;(b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
- 40. A host cell transformed with the recombinant vector of claim 36.
- 41. A host cell transformed with the recombinant vector of claim 37.
- 42. A host cell transformed with the recombinant vector of claim 38.
- 43. A host cell transformed with the recombinant vector of claim 39.
- 44. A method of producing a recombinant multiple epitope fusion antigen comprising:
(a) providing a population of host cells according to claim 40; and (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
- 45. A method of producing a recombinant multiple epitope fusion antigen comprising:
(a) providing a population of host cells according to claim 41; and (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
- 46. A method of producing a recombinant multiple epitope fusion antigen comprising:
(a) providing a population of host cells according to claim 42; and (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
- 47. A method of producing a recombinant multiple epitope fusion antigen comprising:
(a) providing a population of host cells according to claim 43; and (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to provisional patent application Ser. Nos. 60/212,082, filed Jun. 15, 2000; 60/280,811, filed Apr. 2, 2001; and 60/280,867, filed Apr. 2, 2001, from which applications priority is claimed under 35 USC §119(e)(1) and which applications are incorporated herein by reference in their entireties.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60212082 |
Jun 2000 |
US |
|
60280811 |
Apr 2001 |
US |
|
60280867 |
Apr 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09881654 |
Jun 2001 |
US |
Child |
10637323 |
Aug 2003 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10637323 |
Aug 2003 |
US |
Child |
10899715 |
Jul 2004 |
US |